7/24/2008

Novartis has extended its collaboration with Alnylam Therapeutics and Roche has purchased gene-silencing specialist Mirus Bio Corp., an indication that the drug industry recognizes the research and commercial possibilities in RNAi-based therapeutics for a range of diseases. A Novartis official said RNAi "holds great potential," adding, "In particular, this new area of biology has potential to treat diseases that have not been able to be addressed by traditional approaches."

Full Story:
InPharm.com

Related Summaries